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Objective: Differential diagnosis of neuromyelitis optica spectrum disorders (NMOSD)
and multiple sclerosis (MS) or mimics can be challenging, especially in patients with
atypical presentations and negative serostatus for aquaporin-4 antibodies (AQP4-Ab).
This brief research report describes magnetic resonance imaging (MRI) findings focusing
on quantitative apparent diffusion coefficient (ADC) histogram analysis as a potential tool
to differentiate NMOSD from MS.
Methods: Longitudinal MRI data obtained during routine clinical examinations were
retrospectively analyzed in a patient with histologically determined cerebral NMOSD,
a patient with an acute tumefactive MS lesion, and a patient with ischemic stroke.
Histogram analyses of ADC maps were evaluated.
Results: A patient diagnosed with MS experienced a severe rebound after fingolimod
withdrawal and a single daclizumab injection. Cerebral NMOSD manifestation was
confirmed by brain biopsy. However, the patient did not fulfill consensus criteria for
NMOSD and was AQP4-Ab negative. Comparison of ADC histogram analyses of this
patient with those from a patient with MS and one with ischemic stroke revealed
differential ADC characteristics: namely a more pronounced and prolonged ADC leftward
shift in inflammatory than in ischemic pathology, even more accentuated in NMOSD
versus MS.
Conclusion: ADC map histograms and ADC threshold values for different conditions
may be useful for differentiation of large inflammatory brain lesions and further studies
are merited.
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INTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD) and multiple
sclerosis (MS) are inflammatory disorders of the central nervous
system (CNS) that can have clinical and radiological overlaps.
Differential diagnosis can be challenging, especially in patients
with NMOSD who test negative for aquaporin-4 antibodies
(AQP4-Ab, up to 20%) (1–3). This is a matter of high clinical
relevance as MS drugs may not only lack efficacy in patients with
NMOSD but might even be harmful (4–7). Additional objective
markers that distinguish AQP4-Ab-negative NMOSD from MS
are thus needed.
We report on a patient treated for relapsing–remitting MS
(RRMS) who experienced a severe rebound of an inflammatory
CNS disorder after cessation of fingolimod and overlapping
initiation of daclizumab. In this patient with negative serum
AQP4-Ab and anti-myelin-oligodendrocyte-glycoprotein
(MOG-)Ab, brain biopsy revealed neuropathological
characteristics of NMOSD.
Acute demyelinating CNS lesions are described as exhibiting
restricted diffusion (8). Nevertheless, routinemagnetic resonance
imaging (MRI) including diffusion-weighted sequences cannot
differentiate between acute inflammatory and ischemic entities.
Therefore, textural analysis methods in MRI are receiving
increased attention. We discuss the potential use of quantitative
apparent diffusion coefficient (ADC) histogram analysis on
cranial MRI as a diagnostic tool that may aid in differentiation
between MS and NMOSD.
METHODS
The local ethics committee (Kantonale Ethikkommission Bern,
Switzerland, KEK-BE reg. no. 2016-02035, 2017-01369) gave
approval for access to and use of the patient data for retrospective
clinical research. All data presented were obtained during
routine clinical investigations and retrospectively analyzed in a
pseudonymized fashion.
A retrospective case analysis of an NMOSD patient followed
the clinical evolution, paraclinical findings, and MRI results.
A longitudinal case study using quantitative MRI analysis was
performed to compare the NMOSD patient with an RRMS
patient during relapse, and a patient with acute ischemic stroke.
The routine clinical MRI protocol for MS included the
following non-contrast sequences: diffusion-weighted imaging,
3D T1wMP-RAGE and 3D T2w GRE. After contrast application,
PD/T2w, axial T1w SE, and 3D T1w MP-RAGE were acquired.
ADC maps were evaluated longitudinally (b = 0, b = 1,000
s/mm2, monoexponential ADC calculation) on a pixel-by-pixel
basis for the diffusion-restricted area and used for histogram
analysis (9). For the analysis of the ADC maps, we used
commercially available software for automated and multivendor
Abbreviations: ADC, apparent diffusion coefficient; CNS, central nervous system;
CSF, cerebrospinal fluid; DWI, diffusion-weighted imaging; LETM, longitudinal
extensive transverse myelitis; MS, multiple sclerosis; NMO, neuromyelitis optica;
NMOSD, neuromyelitis optica spectrum disorder; OCB, oligoclonal bands; PCR,
polymerase chain reaction; PLEX, plasma exchange; ROI, region of interest.
postprocessing (Olea Sphere R©, version number 3.0-SP11). The
lesion voxels collected from the contoured regions of interest
(ROIs) provided histograms from which dispersion parameters
were computed (9). For all measurements, we used the ADCs
provided by the imaging system, with a reference value for water
of 2.3× 10−9 m2/s.
Each MRI examination generated multiple sections with
abnormal ROIs. Skewness and kurtosis derived from the
histograms reflected the shape of each histogram. Kurtosis is
a measure of the peak of the histogram. It is zero if there is
a Gaussian distribution, positive if it has a sharp peak, and
negative if it has a flat plateau. Skewness is a measurement of the
histogram asymmetry. It is zero when the majority of the data are
concentrated in the midline, positive if the majority of data are
concentrated to the left of the mean, and negative if the majority
of data are concentrated to the right of the mean.
RESULTS
Clinical Findings
Our patient was diagnosed with RRMS in 2002 after a severe
first relapse with hemiparesis on the right side. She was treated
with interferon-beta from 2003 until 2015. Owing to insufficient
clinical response and continuing relapse activity, as well as side
effects, her treatment was switched to fingolimod in 2015. Relapse
phenotypes were described by the patient as having included
optic neuritis (right) and coordination problems with the right
hand. During fingolimod treatment, ongoing MRI activity was
detected. In 2016, the fingolimod dosage was reduced due to
lymphopenia (0.5mg, 5 times a week). Since the lymphopenia
did not resolve, fingolimod was finally stopped in March 2017
(last documented lymphocyte value 0.38 G/l) and daclizumab
was started at the end of April 2017 (documented normalization
of lymphocyte count to 1.37 G/l). Only 7 days after the first
administration of daclizumab, severe progressive neurological
deterioration occurred. The patient initially showed quadrant
anopsia (lower right quadrant), which progressed rapidly despite
early initiation of high-dose steroids. When she was referred to
our hospital only 2 days later, the patient showed hemiplegia with
neglect and hemianopsia (right), global aphasia, dysphagia and
reduced consciousness (EDSS 9.5).
Over the course of 15 days, the five MR brain scans of
our patient conducted within this period revealed markedly
progressive T2/FLAIR-hyperintense signal alterations in the left
hemisphere from the frontoparietal region to the occipital lobe
with increasing patchy contrast enhancement in the confluent
lesion.
Laboratory Findings
CSF analysis demonstrated 25 cells/µl with lympho-monocytic
pleocytosis and presence of CSF-specific oligoclonal bands
(OCB). Highly sensitive polymerase chain reaction (PCR)
detected neither JC virus DNA nor HSV or VZV DNA.
The results of serological screening for infectious agents were
negative (hepatitis B/C, HIV, Borrelia burgdorferi, Treponema
pallidum, Mycobacterium tuberculosis). Differential screening
tests for vasculitis and connectivitis were negative. Repeated
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testing for AQP4-Ab (cell-based assay: IIFT, Euroimmun AG,
Lübeck, Germany) was negative. Retrospective testing of the first
plasma exchange (PLEX) specimen was negative for AQP4-Ab
and MOG-Ab. All tests were performed after admission to our
hospital following a previous pulsed steroid treatment at another
location.
Brain Biopsy
Brain biopsy was performed due to further deterioration
despite two high-dose steroid pulses and seven sessions of
plasma exchange, presenting with a seizure of focal onset.
The biopsy showed an inflammatory demyelinating lesion
(Supplementary Material). The inflammatory infiltrate
consisted of numerous macrophages with macrophage-
derived foam cells, and a CD8+-dominated T cell infiltrate.
The demyelination was patchy. Strikingly, the lesion showed
astropathic changes with a reduction of astrocytes and AQP4
loss within the lesion areas. These changes are typical for
NMOSD, but not for MS. Also typical for NMOSD, was loss
of oligodendrocytes. CD20-positive B-cells were found in
perivascular compartments. Complement or immunoglobulin
(Ig) deposits around vessels or eosinophils within lesions—
changes observed especially in early active NMOSD
lesions—were not present (10). The brain biopsy showed
no evidence for progressive multifocal leukoencephalopathy or
lymphoma.
Clinical Evolution
The patient initially received acyclovir as a co-treatment; and
sequentially high-dose pulsed steroids and PLEX. Beginning
clinical remission was noted. Follow-up MRI 1 month later
showed that the lesion extent had decreased. With the
help of extensive rehabilitation therapy, the patient further
improved (last documented EDSS 5.0). Long-term treatment
with rituximab was initiated 8 weeks after symptom onset
(total dosage 1,500mg) and the patient exhibited clinical and
radiological stability at the time of writing (after approximately
6 months of follow-up).
ADC Histogram: Differences Between
Entities
Head MRI on admission (before biopsy) indicated a large
FLAIR hyperintense and diffusion-restricted periventricular
white matter lesion located in the parietal, occipital and frontal
lobe with faint contrast enhancement in the anterior portion of
the lesion (Figure 1A). Spinal MRI showed a non-enhancing T2-
hyperintense lesion at the C3–4 level, which had been noted on
previous scans, and two focal non-enhancing lesions in the conus
medullaris.
To detect potential differences in MRI features between
patients with NMOSD, MS, and ischemic stroke, we compared
longitudinal MRI data from our NMOSD patient, acquired in
the acute phase (day 3 from symptom onset; Figure 1A), with
an RRMS patient who had an acute tumefactive MS lesion
(Figure 1B) and a patient who had had an acute ischemic stroke
(Figure 1C).
In the patient with histopathological features of NMOSD,
the ADC maps showed restricted periventricular diffusion in
the frontal, parietal and occipital lobe with corresponding
signal abnormalities on FLAIR-weighted imaging and mild focal
contrast enhancement. Similarly, in the RRMS patient with
a tumefactive MS lesion, there was a periventricular ADC
restriction in the frontal, parietal, and occipital lobe and in the
splenium. This, again, was associated with corresponding signal
abnormalities on FLAIR-weighted imaging and diffuse focal
contrast enhancement. Quantitative ADC maps for the patient
with acute ischemic stroke showed restricted periventricular
diffusion in the caudate nucleus and in the frontal lobe, and signal
abnormalities on FLAIR-weighted imaging, but no contrast
enhancement. The signal characteristics of FLAIR and ADCwere
similar and thus could not be used to differentiate between the
entities.
All three patients underwent several follow-up MRIs with
anatomic and diffusion-weighted sequences. The mean ROI-
based ADC values, skewness and kurtosis were determined from
the MRIs from the patients with brain lesions and ischemic
stroke, respectively (see Supplementary Material). ADC values
were reduced in NMOSD, MS and ischemic stroke, with a
corresponding skewness of the ADC histograms when compared
with normal tissue (normal white matter ADC values range from
670 to 800∗10−6mm2/s). (11) In this one-to-one, days-after-onset
comparison and follow-up, the leftward shift in the NMOSD
patient was more distinct and prolonged than those seen in the
MS and ischemic stroke patients (Figures 2A–C). Skewness in the
patient with ischemic stroke was markedly less pronounced than
in those with MS and NMOSD.
DISCUSSION
We describe a patient with histopathological changes typical of
NMOSD with clear astrocytopathy and AQP4 loss. However,
this patient did not fulfill the diagnostic consensus criteria for
NMOSD, (2) meeting only one clinical core criterion (cerebral
manifestation), and showing absence of longitudinal extensive
transverse myelitis (LETM) or clear optic neuritis, and AQP4-Ab
negativity.
The classical structural pattern of NMOSD is extensive lesions,
particularly in the spinal cord (presenting as LETM) and the
optic nerve. However, revised diagnostic criteria emphasize other
sites of inflammation such as the area postrema, brainstem, and
diencephalon, as well as cerebral manifestations (2).
In retrospect, the history of optic neuritis—described by the
patient, but not distinctly mentioned in her previous medical
records—might have led NMOSD to be considered earlier.
However, optic neuritis is a very common symptom in MS too,
and only now is MRI able to demonstrate different patterns
of optic neuritis in MS versus NMOSD (2). An imaging-based
differential diagnosis with older scans would thus have been be
highly unlikely.
The patient was seronegative for both AQP4-Ab andMOG-Ab
assessed in a cell-based assay. Up to 20% of NMOSD patients are
seronegative (3). As immunomodulatory treatments including
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FIGURE 1 | MRI in the acute phase of NMOSD (A), tumefactive MS (B), and ischemic stroke (C). (A–C): Apparent diffusion coefficient (ADC) map (left), transverse
FLAIR-attenuated inversion recovery weighted scan (middle), transverse contrast-enhanced T1 weighted scan (right) for the NMOSD patient (A), the patient with
tumefactive MS (B) and the patient with ischemic stroke (C). In (B) the contrast enhancement in basal ganglia on the left corresponds to a developmental venous
anomaly.
steroids may influence these results, we cannot exclude false-
negative findings (12). This reflects a common clinical dilemma
as the diagnostic process often runs in parallel with already
administered acute treatments.
In this case, the additional diagnostic findings, especially the
CSF results showing lympho-monocytic pleocytosis and presence
of CSF-specific OCB, did not help in differentiating NMOSD
from MS. For OCB, frequencies up to 30% in NMOSD patients
have been reported (3).
Interestingly, in our patient’s previous MRI scans, brain
pathology before the current attack was not highly suggestive
of long-standing MS. Scans over the 15-years disease course
demonstrated only a few rather unspecific lesions, except for
one larger lesion adjacent to the left ventricle. The overall lesion
burden was thus low. The spinal cord had focal, non-LETM
lesions. This is usually considered as being MS-specific; however,
short transverse myelitis is also a common phenomenon in
NMOSD and has been found to delay diagnosis and treatment
of NMOSD (13).
NMOSD with cerebral pathology was only differentiated from
MS, after 15 years of disease course, by brain biopsy. Even so, not
all the described features of NMOSD were found in the biopsy
material (10). This again might have been influenced by both
the timing of the biopsy and previous administration of acute
treatments including steroids and plasma exchange. Eosinophilic
infiltration and complement or Ig deposition as markers of early
active lesions were thus not detectable. However, the pattern of
extensive macrophage infiltration, loss of AQP4, astrocytes and
oligodendrocytes, together with perivascular B-cell infiltration
was highly suggestive.
The lack of typical LETM or clear optic neuritis and
negative AQP4-Ab together with the suboptimal response
to treatment with interferon-beta and fingolimod may never
have led to consideration of NMOSD, as this is also seen
in MS. However, after cessation of fingolimod, severe disease
exacerbation was noted. This rebound phenomenon has
recently been described in MS patients, (14–16) but also as
a potentially severe phenomenon in patients with NMOSD
(6). In our patient, rebound occurred sooner than reported
in the literature. Early re-initiation of therapy, within 1
month, with a highly active compound, daclizumab, could
not prevent fingolimod-associated rebound. As there is no
information on IL-2 receptor blockade in NMOSD patients,
it is not known whether daclizumab might have propagated
the rebound. Given the short latency between the first and
only injection of daclizumab and symptom onset, causality
seemed unlikely. However, in light of the recent withdrawal
from the market of daclizumab following eight cases of serious
inflammatory brain disorders, (17) this possibility might need to
be reconsidered once further information on these cases becomes
available.
Anatomical MRI findings of brain lesions can be typical
of both NMOSD and MS (18). In particular, for intracranial
NMOSD manifestation, cases with occipital lesions similar
to our patient have been reported (19, 20). Involvement of
the splenium in an “arch bridge pattern” as seen in the
MS patient is actually more prevalent in NMOSD patients
(18). Lesion enhancement in seronegative NMOSD patients
is more prevalent than in seropositive ones, complicating
both radiological and clinical differential diagnosis of large
inflammatory brain lesions (21, 22).While asymptomatic or post-
acute NMOSD brain lesions typically show high intensity on both
DWI and ADC, there is a lack of literature about DWI and ADC
imaging characteristics of symptomatic NMOSD brain lesions
(23).
We compared the MRI characteristics of our patient to
MRIs from patients with MS and ischemic stroke. NMOSD
lesions display a loss of astrocytes (20, 24) as was evident in
the biopsy material from our patient, which is atypical for
MS. However, in anatomical MRI, this is not well represented.
Quantitative and longitudinal MR analysis may further aid in this
respect (9, 25).
Skewness and kurtosis are relatively simple parameters that
describe texture heterogeneity. Computer-aided texture analysis
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FIGURE 2 | ROI mean ADC signal intensity of NMOSD (A), tumefactive MS (B), and ischemic stroke (C). Mean ADC values of abnormal ROIs in NMOSD (2A), MS
(2B) and ischemic stroke (2C) at the time of initial MR and at follow-up; with histogram analysis for comparison.
shows promise as a method for lesion characterization. It assesses
and quantifies lesion characteristics using pixel values and/or
their distribution within target lesions, providing a more detailed
and reproducible quantitative assessment than is possible from
visual analysis by human observers.
In our case comparison, a difference in ADC map
histograms was detected. Skewness in ischemic stroke
is markedly less pronounced than in MS and NMOSD.
The texture parameter skewness may help to distinguish
between these diseases. The difference can be summarized as
a more pronounced and prolonged skewness in inflammatory
brain pathology than in stroke and seems to be even more
pronounced and prolonged in NMOSD than in MS. It is
important to bear in mind that these are only observations
in single patients and confirmation from larger studies is
necessary.
However, in several tumor studies, texture analysis with
different imaging modalities has been shown to reflect tumor
heterogeneity and was reported to be able to distinguish between
multiple features—including imaging parameters, pathological
subtypes, and genetic profiles—in various types of tumors
(26–28). Therefore, in oncological imaging, textural analysis
methods are already well established. Tumor heterogeneity can
be caused by variations in cellularity, angiogenesis, extracellular
matrix, or necrosis (29). Thus, quantification of ADC map
histograms and definition of ADC threshold values for different
diseases might represent a prospective, useful noninvasive
imaging tool for differentiation of large inflammatory brain
lesions. This should be further evaluated in future studies.
Earlier differentiation could allow patients to be selected
sooner and directed more quickly to the most appropriate
treatment.
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CONCLUSION
ADC map histograms and ADC threshold values for different
conditionsmay be useful for differentiation of large inflammatory
brain lesions and further studies are merited.
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